151 related articles for article (PubMed ID: 19016765)
1. CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients.
Lal S; Sandanaraj E; Wong ZW; Ang PC; Wong NS; Lee EJ; Chowbay B
Cancer Sci; 2008 Oct; 99(10):2045-54. PubMed ID: 19016765
[TBL] [Abstract][Full Text] [Related]
2. Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients.
Lal S; Wong ZW; Jada SR; Xiang X; Chen Shu X; Ang PC; Figg WD; Lee EJ; Chowbay B
Pharmacogenomics; 2007 Jun; 8(6):567-75. PubMed ID: 17559346
[TBL] [Abstract][Full Text] [Related]
3. Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity.
Fan L; Goh BC; Wong CI; Sukri N; Lim SE; Tan SH; Guo JY; Lim R; Yap HL; Khoo YM; Iau P; Lee HS; Lee SC
Pharmacogenet Genomics; 2008 Jul; 18(7):621-31. PubMed ID: 18551042
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics of ABCB5, ABCC5 and RLIP76 and doxorubicin pharmacokinetics in Asian breast cancer patients.
Lal S; Sutiman N; Ooi LL; Wong ZW; Wong NS; Ang PCS; Chowbay B
Pharmacogenomics J; 2017 Jul; 17(4):337-343. PubMed ID: 26975227
[TBL] [Abstract][Full Text] [Related]
5. Correlation of aldo-ketoreductase (AKR) 1C3 genetic variant with doxorubicin pharmacodynamics in Asian breast cancer patients.
Voon PJ; Yap HL; Ma CY; Lu F; Wong AL; Sapari NS; Soong R; Soh TI; Goh BC; Lee HS; Lee SC
Br J Clin Pharmacol; 2013 Jun; 75(6):1497-505. PubMed ID: 23116553
[TBL] [Abstract][Full Text] [Related]
6. Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients.
Lal S; Wong ZW; Sandanaraj E; Xiang X; Ang PC; Lee EJ; Chowbay B
Cancer Sci; 2008 Apr; 99(4):816-23. PubMed ID: 18377430
[TBL] [Abstract][Full Text] [Related]
7. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group.
Blanco JG; Sun CL; Landier W; Chen L; Esparza-Duran D; Leisenring W; Mays A; Friedman DL; Ginsberg JP; Hudson MM; Neglia JP; Oeffinger KC; Ritchey AK; Villaluna D; Relling MV; Bhatia S
J Clin Oncol; 2012 May; 30(13):1415-21. PubMed ID: 22124095
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetics of target genes across doxorubicin disposition pathway: a review.
Lal S; Mahajan A; Chen WN; Chowbay B
Curr Drug Metab; 2010 Jan; 11(1):115-28. PubMed ID: 20302569
[TBL] [Abstract][Full Text] [Related]
9. Carbonyl reductase 1 expression influences daunorubicin metabolism in acute myeloid leukemia.
Varatharajan S; Abraham A; Zhang W; Shaji RV; Ahmed R; Abraham A; George B; Srivastava A; Chandy M; Mathews V; Balasubramanian P
Eur J Clin Pharmacol; 2012 Dec; 68(12):1577-86. PubMed ID: 22562609
[TBL] [Abstract][Full Text] [Related]
10. PXR pharmacogenetics: association of haplotypes with hepatic CYP3A4 and ABCB1 messenger RNA expression and doxorubicin clearance in Asian breast cancer patients.
Sandanaraj E; Lal S; Selvarajan V; Ooi LL; Wong ZW; Wong NS; Ang PC; Lee EJ; Chowbay B
Clin Cancer Res; 2008 Nov; 14(21):7116-26. PubMed ID: 18981011
[TBL] [Abstract][Full Text] [Related]
11. Protection from doxorubicin-induced cardiac toxicity in mice with a null allele of carbonyl reductase 1.
Olson LE; Bedja D; Alvey SJ; Cardounel AJ; Gabrielson KL; Reeves RH
Cancer Res; 2003 Oct; 63(20):6602-6. PubMed ID: 14583452
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic evaluation of doxorubicin plasma levels in normal and overweight patients with breast cancer and simulation of dose adjustment by different indexes of body mass.
Barpe DR; Rosa DD; Froehlich PE
Eur J Pharm Sci; 2010 Nov; 41(3-4):458-63. PubMed ID: 20688160
[TBL] [Abstract][Full Text] [Related]
13. Sex differences in improved efficacy of doxorubicin chemotherapy in Cbr1+/- mice.
Freeland MM; Angulo J; Davis AL; Flook AM; Garcia BL; King NA; Mangibin SK; Paul KM; Prosser ME; Sata N; Bentley JL; Olson LE
Anticancer Drugs; 2012 Jul; 23(6):584-9. PubMed ID: 22343424
[TBL] [Abstract][Full Text] [Related]
14. Carbonyl Reductase 1 Plays a Significant Role in Converting Doxorubicin to Cardiotoxic Doxorubicinol in Mouse Liver, but the Majority of the Doxorubicinol-Forming Activity Remains Unidentified.
Breysse DH; Boone RM; Long CM; Merrill ME; Schaupp CM; White CC; Kavanagh TJ; Schmidt EE; Merrill GF
Drug Metab Dispos; 2020 Mar; 48(3):187-197. PubMed ID: 31955137
[TBL] [Abstract][Full Text] [Related]
15. Metabolism of doxorubicin to the cardiotoxic metabolite doxorubicinol is increased in a mouse model of chronic glutathione deficiency: A potential role for carbonyl reductase 3.
Schaupp CM; White CC; Merrill GF; Kavanagh TJ
Chem Biol Interact; 2015 Jun; 234():154-61. PubMed ID: 25446851
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of Daunorubicin in adult patients with acute myeloid leukemia.
Varatharajan S; Panetta JC; Abraham A; Karathedath S; Mohanan E; Lakshmi KM; Arthur N; Srivastava VM; Nemani S; George B; Srivastava A; Mathews V; Balasubramanian P
Cancer Chemother Pharmacol; 2016 Nov; 78(5):1051-1058. PubMed ID: 27738808
[TBL] [Abstract][Full Text] [Related]
17. Influence of SLCO1B3 haplotype-tag SNPs on docetaxel disposition in Chinese nasopharyngeal cancer patients.
Chew SC; Sandanaraj E; Singh O; Chen X; Tan EH; Lim WT; Lee EJ; Chowbay B
Br J Clin Pharmacol; 2012 Apr; 73(4):606-18. PubMed ID: 21995462
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacokinetic profile of high-dose doxorubicin administered during a 6 h intravenous infusion in breast cancer patients].
Wihlm J; Limacher JM; Levêque D; Duclos B; Dufour P; Bergerat JP; Methlin G
Bull Cancer; 1997 Jun; 84(6):603-8. PubMed ID: 9295863
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patients.
Xiang X; Jada SR; Li HH; Fan L; Tham LS; Wong CI; Lee SC; Lim R; Zhou QY; Goh BC; Tan EH; Chowbay B
Pharmacogenet Genomics; 2006 Sep; 16(9):683-91. PubMed ID: 16906022
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer.
Swenson CE; Bolcsak LE; Batist G; Guthrie TH; Tkaczuk KH; Boxenbaum H; Welles L; Chow SC; Bhamra R; Chaikin P
Anticancer Drugs; 2003 Mar; 14(3):239-46. PubMed ID: 12634619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
